EGFR-TKI治疗EGFR敏感基因突变型NSCLC的疗效及对患者血清CEA、CA-125和NSE水平的影响  

Efficacy of EGFR-TKI in the Treatment of EGFR-sensitive Gene Mutant NSCLC and Its Effect on Serum CEA,CA-125 and NSE Levels

作　　者：黄晓[1] 王少芳[1] 张军营 HUANG Xiao;WANG Shaofang;ZHANG Junying(Anyang People's Hospital,Anyang,455000)

机构地区：[1]河南省安阳市人民医院,455000

出　　处：《实用癌症杂志》2021年第4期624-627,共4页The Practical Journal of Cancer

基　　金：北京白求恩医学科学研究基金(编号:SCZ029AN)。

摘　　要：目的探讨EGFR-TKI治疗EGFR敏感基因突变型NSCLC的临床疗效,并对患者治疗前后肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)及神经元特异性烯醇化酶(NSE)水平的变化情况进行分析。方法以108例EGFR敏感基因突变型NSCLC患者为研究对象,采用随机数字表法分为常规组和治疗组。常规组患者56例,进行基础化疗(吉西他滨+顺铂);治疗组患者52例,在化疗的基础上接受EGFR-TKI(吉非替尼或厄洛替尼)治疗,对其临床疗效、血清肿瘤标志(CEA、CA-125和NSE)以及不良反应进行观察和统计。结果治疗组的总有效率为90.38%,显著高于常规组的75.00%(P<0.05)。治疗前,2组患者CEA、CA-125和NSE水平无显著差别(P>0.05),经治疗,2组各项肿瘤标志物水平均显著降低(P<0.05),且治疗组中CEA、CA-125和NSE水平均显著低于常规组(P<0.05)。常规组和治疗组均有恶心、骨髓移植、低血压、皮疹、腹泻以及胃脘部不适等不良反应,2组比较无显著差异(P>0.05)。结论EGFR-TKI对EGFR敏感基因突变型NSCLC有较好的临床疗效,能显著降低患者CEA、CA-125和NSE水平。Objective To investigate the clinical efficacy of EGFR-TKI in the treatment of EGFR-sensitive gene mutant NSCLC and analyze the changes in the levels of tumor markers cancer blank antigen(CEA),carbohydrate antigen 125(CA125)and neuron-specific enolase(NSE)before and after treatment.Methods 108 cases of NSCLC patients with EGFR-sensitive gene mutations as the research objects,and they were divided into the routine group and the treatment group by random number table method.56 patients in the routine group received basic chemotherapy(gemcitabine+cisplatin),and 52 patients in the treatment group received EGFR-TKI(gefitinib or erlotinib)treatment on the basis of chemotherapy.And its clinical efficacy,serum tumor markers(CEA,CA-125 and NSE)and adverse reactions were observed and counted.Results The total effective rate of the treatment group was 90.38%,which was significantly higher than the 75.00%of the conventional group(P<0.05).Before treatment,there was no significant difference in the levels of CEA,CA-125 and NSE between the 2 groups(P>0.05).After treatment,the levels of tumor markers in the 2 groups were significantly reduced(P<0.05).In the treatment group,CEA and CA-125 and NSE levels were significantly lower than those in the conventional group(P<0.05).Both the conventional group and the treatment group had adverse reactions such as nausea,bone marrow transplantation,hypotension,skin rash,diarrhea and gastric cavity discomfort,and there was no significant difference between the 2 groups(P>0.05).Conclusion EGFR-TKI has a good clinical effect on EGFR-sensitive gene mutant NSCLC and can significantly reduce the level of CEA,CA-125 and NSE in patients.

关 键 词：EGFR-TKI EGFR敏感基因突变型 NSCLC 疗效 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]